Irofulven

Real-world outcomes of first-line chemotherapy for unresectable stage III and IV bladder cancer, effectiveness of chemotherapy in elderly patients with metastatic bladder cancer, treatment patterns and survival outcomes for first- and second-line treatment in locally advanced and metastatic urothelial cancer patients, enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer, nivolumab plus gemcitabine–cisplatin in advanced urothelial carcinoma, biomarker-oriented therapy in bladder and renal cancer, predictive and prognostic biomarkers for targeted therapy in metastatic urothelial cancer, identification of a synthetic lethal relationship between nucleotide excision repair deficiency and irofulven sensitivity in urothelial cancer, anti-tumour compounds inducing DNA lesions exclusively processed by transcription- and replication-coupled repair pathways, cell cycle effects and induction of premitotic apoptosis by irofulven in synchronized cancer cells, targeting germline- and tumor-associated nucleotide excision repair defects in cancer, somatic ERCC2 mutations correlating with cisplatin sensitivity in muscle-invasive bladder cancer, comprehensive molecular characterization of muscle-invasive bladder cancer, and clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma.